Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | G469V |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | BRAF G469V is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469V results in increased Braf kinase activity and activation of downstream MEK and ERK in cell culture (PMID: 28947956, PMID: 26343582, PMID: 28783719), and in one of two cell lines, increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785). |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF G469V BRAF mutant BRAF G469X BRAF G469V |
Transcript | NM_004333.6 |
gDNA | chr7:g.140781602C>A |
cDNA | c.1406G>T |
Protein | p.G469V |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001378474.1 | chr7:g.140781602C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140781602C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
XM_047420769.1 | chr7:g.140781602C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140781602C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140781602C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140781602C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140781602C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140781602C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
NM_001378470.1 | chr7:g.140778000C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
NM_001378467.1 | chr7:g.140781611C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140781602C>A | c.1406G>T | p.G469V | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03843775 | Phase Ib/II | Binimetinib + Encorafenib | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | Completed | USA | 0 |